Dna Mismatch Repair

DNA mismatch repair (MMR) is a highly conserved repair pathway that plays an of import role in the detection and correction of errors created during/after Deoxyribonucleic acid replication (i.e., post-replication repair) and/or later natural genetic recombination events.

From: DNA Repair in Cancer Therapy , 2012

Deoxyribonucleic acid Mismatch Repair: Mechanisms and Cancer Genetics☆

William J. Graham V , ... Richard D. Kolodner , in Encyclopedia of Cancer (Tertiary Edition), 2022

Summary

MMR is a conserved pathway that repairs base–base mismatches and pocket-size insertion/deletions caused by misincorporation errors during DNA replication. The MMR pathway works through mispair detection past the partially redundant complexes MSH2-MSH6 and MSH2-MSH3, followed past recruitment of downstream proteins that excise the error-containing DNA strand and resynthesize information technology correctly. Two sub-pathways of MMR exist: the EXO1-dependent pathway that relies on Deoxyribonucleic acid excision past EXO1, and a less well characterized EXO1-independent pathway. Defects in MMR atomic number 82 to greatly elevated mutation rates that in plow tin bulldoze carcinogenesis. Lynch syndrome is a common hereditary cancer predisposition syndrome caused by heterozygous MMR defects that is near ofttimes characterized past early on onset colorectal cancers and many other types of cancer. Some other, rarer, cancer predisposition syndrome, BMMR-D is caused past homozygous MMR defects and results in a number of types of early onset cancers. The most common causes of these syndromes defects in MSH2 or MLH1, both of which crusade total MMR defects; less mutual causes are defects in MSH6 and PMS2. MMR defective sporadic cancers of many types have besides been characterized and are primarily due to silencing of the MLH1 gene. The increased mutation rate caused past defective MMR increases the probability of inactivating mutations in tumor suppressor or proto-oncogenes, leading to increased development of cancer. Identifying MMR defects in patients has of import implications for cancer surveillance in affected families and for cancer treatment, both in terms of avoiding drugs that MMR defective tumors are resistant to and using new treatments that may effectively target MMR defective tumors.

Read full affiliate

URL:

https://www.sciencedirect.com/science/article/pii/B9780128012383961300

DNA Mismatch Repair and the Dna Damage Response

Chiliad.-K. Li , in Encyclopedia of Biological Chemical science (Second Edition), 2022

Abstract

Dna mismatch repair (MMR) plays a critical role in maintaining genomic integrity. Defects in MMR predispose to cancer. In the past, the power of the MMR system to correct mismatches was considered the primary mechanism past which information technology contributes to genomic stability. However, recent studies reveal that MMR also contributes to genome stability by mediating Deoxyribonucleic acid impairment signaling in response to Deoxyribonucleic acid damaging agents. MMR initiation factors MutSα and MutLα recognize DNA lesions and trigger a signaling cascade that involves a series of protein kinases and effectors for prison cell cycle arrest and/or apoptosis. This process eliminates damaged cells from the body, preventing tumorigenesis.

Read full affiliate

URL:

https://world wide web.sciencedirect.com/science/commodity/pii/B9780123786302002383

DNA Repair Pathways and Man Cancer

Alan D. D'Andrea , in The Molecular Ground of Cancer (Fourth Edition), 2022

Mismatch Repair (MMR)

MMR has been reviewed by Modrich. half-dozen MMR rapidly removes mispaired nucleotides that result from replication errors and is also involved in the detection and repair of Dna adducts such as those resulting from platinum-based chemotherapeutic agents. Initially, the heterodimeric MSH circuitous recognizes the nucleotide mismatch, followed by its interaction with MLH1/PMS2 and MLH1/MLH3 complexes. Several proteins participate in the process of nucleotide excision and resynthesis. Tumor cells deficient in MMR take much college mutation frequencies than normal cells and exhibit microsatellite instability, a genomic biomarker of the underlying defect. Patients with the genetic affliction HNPCC (hereditary nonpolyposis colon cancer) take germline mutations of MMR genes and are predisposed to MMR-deficient colon cancers. Recent studies suggest that MMR-deficient cells may be hypersensitive to inhibitors of various DNA polymerases, such every bit POLB and POLG. 15 At least half dozen genes—MSH2, MLH1, PMS2, MSH3, MSH6, and MLH3—are involved in mismatch repair. A schematic representation of MMR is shown in Figure 4-ii.

Read full affiliate

URL:

https://www.sciencedirect.com/science/article/pii/B9781455740666000044

Genomic Instability and Crumbling

C. Sidler , in Genome Stability, 2022

3.four.ane Mismatch Repair

MMR mainly repairs DNA lesions caused by faulty DNA replication or repair, resulting in mismatches or modest insertion and deletion loops, or deamination of five-methylcytosine. Failure of MMR is often associated with point mutations or microsatellite instability (Fig. 29.1). Both elevated rates of microsatellite instability with increasing age [35,36], and the reduced chapters of cell extracts from old donors to repair induced mismatches [37], betoken an age-dependent decline in MMR activity.

Effigy 29.1. DNA impairment and historic period-related changes in DNA repair.

Unlike DNA-damaging agents that cause different types of DNA damage are listed on top, the repair pathways responsible to fix them in the middle and possible consequences of their dysfunction on the lesser. Arrows next to the repair pathways indicate functional decline with age. The gray circumvolve indicates Deoxyribonucleic acid impairment in the form of bulky adducts.

 Modified from Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411(6835):366–74.

Further, mutations in MMR genes in humans are associated with cancer susceptibility [38]. This may betoken a part for age-dependent decline in MMR in the increasing cancer susceptibility with increasing age.

Read full chapter

URL:

https://www.sciencedirect.com/scientific discipline/commodity/pii/B978012803309800029X

Dna Repair Pathways and Homo Cancer

Alan D. D'Andrea , in The Molecular Footing of Cancer (Third Edition), 2008

Mismatch Repair

MMR has been reviewed (half-dozen). MMR speedily removes mispaired nucleotides that result from replication errors and is involved in the detection and repair of DNA adducts such equally those resulting from platinum-based chemotherapeutic agents. Initially, the heterodimeric MSH complex recognizes the nucleotide mismatch, followed by its interaction with MLH1/PMS2 and MLH1/MLH3 complexes. Several proteins participate in the process of nucleotide excision and resynthesis. Tumor cells deficient in mismatch repair have much higher mutation frequencies than normal cells and showroom microsatellite instability, a genomic biomarker of the underlying defect. At least vi genes, MSH2, MLH1, PMS2, MSH3, MSH6, and MLH3, are involved in mismatch repair. A schematic representation of MMR is shown in Figure 4-2.

Read full chapter

URL:

https://www.sciencedirect.com/scientific discipline/commodity/pii/B9781416037033100044

Dna Mismatch Repair in Affliction and Aging

P. Hsieh , in Encyclopedia of Biological Chemistry (Second Edition), 2022

Abstract

DNA mismatch repair plays a critical function in ensuring the fidelity of DNA replication. Errors during Dna synthesis, if uncorrected, give rise to mutations in the next circular of replication. Deoxyribonucleic acid mismatch repair targets these errors resulting in excision of these misincorporated bases in the newly synthesized DNA strand and resynthesis to restore the right sequence. Inactivating mutations in mismatch repair genes event in a very high rate of spontaneous mutation and are the leading correspondent to the genetic predisposition to colorectal cancer. Loss of mismatch repair is also associated with sporadic colorectal carcinomas. The prevalence of mutation in mismatch repair scarce cells results in the activation of oncogenes and the loss of tumor suppressors. In addition, mismatch repair proteins play of import roles in a diversity of other fundamental cellular processes with significant implications for human being wellness.

Read full chapter

URL:

https://www.sciencedirect.com/science/commodity/pii/B9780123786302003042

Mismatch Repair, Long/Short Patch☆

A.-L. Lu , in Reference Module in Life Sciences, 2022

Introduction

DNA mismatch repair (MMR) systems enhance DNA replication fidelity and/or reduce mutations caused by Dna damage. Long-patch repair systems remove and resynthesize up to hundreds or thousands of nucleotides on a detail Dna strand. Short-patch repair pathways excise certain types of mismatches with a repair tract shorter than 15 nt. Cells lacking in MMR take unstable genome and human individuals bearing germline mutations in MMR genes are prone to cancer and other diseases. Information gleaned from studies of MMR tin help to more finer prevent, diagnose, and care for tumors. In addition, it will identify potential targets that can be exploited clinically for anti-cancer therapies.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780128096338067145

Dna Mismatch Repair in Mammals

A.J. Plys , E. Alani , in Encyclopedia of Biological Chemistry (2nd Edition), 2022

Summary

The MMR organisation monitors the genome during Deoxyribonucleic acid replication to ensure that mistakes made by DNA polymerases are corrected. A large group of repair factors acts in a coordinated fashion to ensure accurate and timely repair. Some details of the repair process, such equally how strand discrimination occurs to specifically remove errors on the newly replicated strand, are still unclear; withal, the development of an in vitro mammalian MMR system from purified components, coupled with prison cell biological analysis of MMR factors, has provided a basic understanding of how MMR leads to mutation abstention and how defects in this procedure tin create a mutational load that can cause affliction. The fact that mutations in many of the key recognition factors in MMR have been implicated in tumorigenesis illustrates the importance of MMR in maintaining mammalian genome stability.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780123786302003157

Lynch Syndrome

Päivi Peltomäki , in Encyclopedia of Cancer (Third Edition), 2022

Temporal Relationship Between MMR Deficiency and Other Tumorigenic Events

MMR defects are among the earliest detectable alterations in cancer-prone target tissues of LS individuals. Intestinal resections for small or large bowel cancer from LS mutation carriers display lesions termed MMR-deficient crypt foci with a frequency of ane focus per 1   cmii of nontumorous mucosa, every bit compared to none in not-LS command patients. MMR protein is absent-minded and MSI is nowadays in such lesions, indicating biallelic MMR cistron inactivation. The abundance of MMR-deficient crypt foci contrasts with the low number of adenomas or carcinomas observed in LS and suggests that nigh lesions do not progress to malignancy. In colorectal polyps from MMR cistron mutation carriers, the prevalence of MMR deficiency increases with the size and dysplasia of adenomatous polyps, from 67% in adenomas with low-degree dysplasia to 100% in adenomas with high-caste dysplasia; the latter frequency is similar to colorectal carcinomas. Hyperplastic polyps from LS individuals rarely (<   5%) display MMR defects and their cancerous potential is considered low. In analogy to colorectal tumorigenesis, the prevalence of MMR defects increases with endometrial tumor progression in LS. Decreased MMR protein expression has been reported to occur in 7% in normal endometrium, 40% in unproblematic hyperplasia, and ∼   100% in complex hyperplasia with or without atypia and likewise in endometrial carcinoma; the frequencies of MSI are somewhat lower.

The observations of abundant MMR-scarce catacomb foci without progression to visible tumors on the one manus and adenoma evolution without biallelic MMR gene inactivation on the other hand imply the need of other oncogenic events besides MMR deficiency. As mentioned earlier, Deoxyribonucleic acid methylation changes tin can be early on events in tumorigenesis. Promoter methylation of SFRP1 and SLC5A8 may form field defects in histologically normal colonic mucosa from LS individuals. Studies on sporadic cases has revealed frequent hypermethylation of SFRP1 and SLC5A8 promoters in abnormal catacomb foci, the earliest detectable morphological lesions of colorectal tumorigenesis that normally lack APC mutations, and methylation is accompanied by decreased expression of the respective proteins. The repair cistron MGMT encoding O6-methylguanine DNA methyltransferase is a farther gene whose loss of expression, usually by promoter methylation, tin form field defects in normal mucosa from LS and sporadic cases. The resulting failure to process mutagenic methyl adducts may trigger cellular transformation past inducing mutations in cancer-related genes such as KRAS or past inactivating the MMR genes by mutations or promoter methylation. Information technology has been postulated that methylation tolerance due to MGMT field defects may initiate sporadic or LS-associated MSI-colorectal cancer prior to MMR deficiency. Every bit, however, no such studies are available that would accept examined the earliest lesions (aberrant crypts) for both MMR and methylation abnormalities, information technology remains unsettled which aberrations come first.

Mutations of APC, an of import gatekeeper of colon tumorigenesis, are known to occur early on in colon tumorigenesis; therefore, this cistron has been used in studies addressing the temporal relationship between MMR defects and other molecular events. Investigations on mice heterozygous for the Apc Min mutation and knockouts for selected MMR genes (Min/+, Msh2   −/− and Min/+, Mlh1   −/− mice) demonstrate that MMR deficiency changes the spectrum of somatic Apc alterations from LOH, the usual second hit, to point mutations, suggesting that deficient MMR exerts its outcome before Apc. On the other hand, comparison of the APC mutation spectra in sporadic MSI and MSS colon cancers has failed to identify in the sometime tumors any clear excess of changes characteristic of MMR defects, such as preferential interest of repeat sequences, suggesting that MMR deficiency occurs after APC mutations. Taken together, studies conducted to date have remained conflicting or inconclusive in an endeavor to make up one's mind the chronological club of MMR defects relative to other molecular events in multistep tumorigenesis.

Read full affiliate

URL:

https://www.sciencedirect.com/science/article/pii/B9780128012383650481

Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies

Stanton L. Gerson , ... Richard J. Creger , in Hematology (Seventh Edition), 2022

Major Molecular Response Mutations and Methylating Agent Resistance

MMR defects in humans were initially described in hereditary nonpolyposis colon cancer, which comprises approximately 15% of all colon cancer, lymphomas, and relapsing acute leukemias. The genetic defect results in a loftier rate of spontaneous mutations within microsatellite Deoxyribonucleic acid, resulting in the RER phenotype arising as the expansion or wrinkle of mono-, di-, or tri-nucleotide repeats within the microsatellites. Tumor cells defective in MMR are remarkably resistant to temozolomide regardless of AGT activity or its inhibition past BG, confirming the importance of MMR in sensitivity to methylating agents. Of interest, MMR mutant cells are likewise two- to threefold resistant to cisplatin, perhaps because the cisplatin Dna adduct is jump by the MMR complex, slowing its recognition and repair by the nucleotide repair pathway and increasing its cytotoxicity. Such MMR-deficient cells likewise showroom microsatellite instability, a measure of genomic instability and the propensity to develop further mutations during therapy, leading to subclones of resistant cells. Loss of PMS2 has been identified in a family unit of babyhood lymphomas. Microsatellite instability is seen in acute leukemias and in T-prison cell leukemias, suggesting both that these malignancies take lost MMR office and that they are more decumbent to drug resistance and acquisition of additional mutations that give rise to farther drug resistance. Evidence of microsatellite instability and loss of MMR is present in some leukemias only is much more than common in treatment-related leukemias, again providing a machinery of drug resistance.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780323357623000573